Anapharm Europe.

Anapharm Europe, PharmaNet officially terminate joint venture PharmaNet Development Group, Inc. And Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic medication and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical providers officially ended December 22, 2010. In conjunction with the termination of the relationship, Dr. Maria Cruz Caturla, Anapharm Europe’s bulk shareholder, has bought PharmaNet’s minority ownership curiosity, thus becoming the sole owner of the company. The companies will continue to invest in independently, and provide to clients, bioanalytical solutions in their respective laboratory facilities.With the potential commercial launch of Pixuvri, coupled with the successful in-licensing of tosedostat, we continue to explore additional novel clinical stage substances to increase our hematologic cancer item pipeline,’ Bianco added. EMA’s CHMP granted a positive opinion for conditional authorization of CTI’s MAA for Pixuvri as monotherapy for the treating adult patients with multiple relapsed or refractory aggressive NHL. The final OPAL phase 2 results of tosedostat, which demonstrated significant response prices in elderly sufferers with relapsed or refractory AML, were presented in an oral program at the American Society of Hematology’s Annual Meeting in 2011.

Other Posts From Category "venereology":

Related Posts